Associated Papers
Proof-of-principle: nanopore adaptive sampling enables full blood group genome analysis and resolution of hybrid alleles.
Gueuning M et al.
Blood Advances, 2026
Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites.
Liu Z et al.
European Journal of Clinical Pharmacology, 2022
ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?
Bruckmueller H et al.
Expert Opinion on Drug Metabolism & Toxicology, 2021
Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
Aboul-Soud MAM et al.
Saudi Journal of Biological Sciences, 2021
Targeted next generation sequencing as a tool for precision medicine.
Gulilat M et al.
Bmc Medical Genomics, 2019
ATP-Binding Cassette Transporters in the Clinical Implementation of Pharmacogenetics.
López-Fernández LA
Journal of Personalized Medicine, 2018
Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.
Chen S et al.
Drug Metabolism Reviews, 2016
Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.
Crona DJ et al.
The Pharmacogenomics Journal, 2016
Genetic variation of the ABC transporter gene ABCC1 (Multidrug resistance protein 1-MRP1) in the Polish population.
Słomka M et al.
Bmc Genetics, 2015
Non-coding polymorphisms in nucleotide binding domain 1 in ABCC1 gene associate with transcript level and survival of patients with breast cancer.
Kunická T et al.
Plos One, 2014
Multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: from discovery to clinical application.
Yin J et al.
Zhong Nan Da Xue Xue Bao. Yi Xue Ban = Journal of Central South University. Medical Sciences, 2011
ABCC1 polymorphism Arg723Gln (2168G> A) is associated with lung cancer susceptibility in a Chinese population.
Yin JY et al.
Clinical and Experimental Pharmacology & Physiology, 2011
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
Innocenti F et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2009
A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function.
Fung KL et al.
Biochimica Et Biophysica Acta, 2009
Pharmacogenetic pathway analysis of irinotecan.
Rosner GL et al.
Clinical Pharmacology and Therapeutics, 2008
Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs.
Cascorbi I
Pharmacology & Therapeutics, 2006
Implications of genetic polymorphisms in drug transporters for pharmacotherapy.
Kerb R
Cancer Letters, 2006
Linkage disequilibrium and haplotype architecture for two ABC transporter genes (ABCC1 and ABCG2) in Chinese population: implications for pharmacogenomic association studies.
Wang H et al.
Annals of Human Genetics, 2004
Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: detection of a novel mutation G816A in the human MRP1 gene.
Oselin K et al.
European Journal of Clinical Pharmacology, 2003
Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects.
Ito S et al.
Pharmacogenetics, 2001
Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution.
Conrad S et al.
Journal of Human Genetics, 2001